Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Name: Kaimen Rigor review — Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.
Item: Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.
Rating: 59
Author: Alpha1

Debily MA, Le Teuff G, Kergrohen T, Varlet P, Castel D, Leblond P, Hargrave D, Nysom K, Blomgren K, McCowage GB, Bautista F, van Vuurden D, Jones C, Mackay A, Izquierdo E, Ziegler DS, Moussa A, Barret E, Puget S, Beccaria K, Aquilina K, Riffaud L, Bolle S, Abbou S, Bertozzi AI, De Carli E, Boddaert N, Dangouloff-Ros V, Calmon R, Blanc P, Vassal G, Le Deley MC, Grill J

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04354-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/fa641dcb-2c36-4303-bc65-4354347a1199" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/fa641dcb-2c36-4303-bc65-4354347a1199/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

faba59d259f111b807a2f665fd7a6d34af97ff722dff735cf20c5f38d98b76c7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Paper source

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary efficacy claim is that the trial was negative for OS, with no significant difference between treatment arms and historical control. However, the paper highlights a subgroup analysis showing that patients with PI3K/AKT/MTOR alterations treated with everolimus had a median OS of 14 months versus 9 months for dasatinib. This effect size is presented without an explicit anchor to a minimal clinically important difference or a clear biological meaningfulness threshold, and it is based on a post-hoc exploratory analysis.
“Patients harboring PIK3/AKT/MTOR pathway mutations, an mTOR activation gene expression signature or 1q gain derived greater benefit from everolimus than from dasatinib, with median OS of 14 months versus 9 months, respectively.”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
49% does not match the reported count 110/233
“110 of 233 patients (49%)”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted randomized phase 2 trial with rigorous design, clear reporting of methods, and appropriate statistical analysis. The main weakness is the lack of an explicit ethics approval statement naming the committee and approval number, and minor reporting gaps such as not explicitly stating the open-label design and not mentioning a reporting guideline.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with N/A for animal-related and cell-line criteria. The statistics verification recomputed only a subset of tests (3 tests, 2 consistent, 1 inconsistent but unspecified), so the statistical analysis is not fully verified.

Numerical inconsistencies

2 findings · worst medium

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks. 1 printed percentage that does not match its own count.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Ethics/consent reporting incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on DIPG molecular characterization, actionable targets (EGFR, mTOR, PDGFRA), and preclinical/clinical evidence for the three drugs. It acknowledges the lack of effective chemotherapy and the need for targeted approaches. The rationale for the trial design is clearly linked to the premise, and limitations of prior single-arm trials are implicitly addressed by the randomized design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on DIPG biology, targeted therapies, and the rationale for biomarker-driven randomization.

Evidence

“In the past two decades, the reintroduction of stereotactic biopsies and increased autopsy studies – have helped identifiy actionable targets, such as PDGFRA – , EGFR , and mTOR .”

Introduction ¶1Find in source

“This included biomarker-driven randomization among three drugs previously tested in phase 1 in patients with DIPG targeting the most frequent druggable alterations known at that time: EGFR tyrosine kinase inhibitor erlotinib, mTOR inhibitor everolimus and multitarget receptor tyrosine kinase inhibitor dasatinib.”

Introduction ¶4Find in source

“The large cohort enabled exploration of disease heterogeneity within a single trial.”

Discussion ¶1Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on DIPG biology, targeted therapies, and the rationale for biomarker-driven randomization.

Evidence

“In the past two decades, the reintroduction of stereotactic biopsies and increased autopsy studies – have helped identifiy actionable targets, such as PDGFRA – , EGFR , and mTOR .”

Introduction ¶1Find in source

Introduction ¶4Find in source

paraphrase[Discussion, paragraph 1]

“Although this trial was negative for the primary endpoint of OS, it prospectively validated prognostic molecular biomarkers previously identified only retrospectively in single-center studies in a homogeneously treated population: H3.1-K27M as a favorable biomarker for survival and TP53 mutations as a strong adverse prognostic biomarker.”

Randomization method is described (biomarker-driven subtrials), and the unit is the patient. Power analysis is provided for the smallest pairwise comparison. Inclusion/exclusion criteria are pre-specified. Blinding is not reported, but the trial is open-label; this is acceptable for a phase 2 oncology trial. Outlier handling is addressed via ITT analysis and missing data handling.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous with clear randomization, pre-specified endpoints, and a power analysis, though blinding is not applicable in this open-label trial.

Evidence

paraphrase[Methods, Trial design and endpoints]

“According to the biomarker constellation present, three randomizations were possible: R1 (erlotinib versus dasatinib) in patients where tumor was EGFR positive without PTEN loss; R2 (everolimus versus dasatinib) in patients where tumor showed only PTEN loss without EGFR overexpression; and R3 (erlotinib versus everolimus versus dasatinib) in patients with tumor showing both EGFR overexpression and PTEN loss.”

“Considering the smallest pairwise comparison (erlotinib versus everolimus), 79 events and 90 patients were required to achieve 80% power to compare OS curves using a two-sided log-rank test ( α = 20%), if the hazard ratio of death was 0.62, equivalent to a 10.6% increase in the 2-year OS (5% versus 15.6%) assuming an exponential survival distribution, proportional hazards and an expected accrual of 22.5 patients per year (East software; Cytel).”

MethodsFind in source

“After diagnosis confirmation (DMG H3K27-altered with an epicenter in the pons) by central pathology reviewer, enrollment in the treatment randomization based on biomarkers was offered in case of age over 6 months, absence of active intratumoral hemorrhage, ability to undergo radiotherapy, Lansky Play Scale >50% and life expectancy longer than 3 months.”

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with clear randomization, power analysis, and inclusion criteria; blinding is not applicable for an open-label trial but is stated.

Evidence

paraphrase[Methods, Trial design and endpoints]

MethodsFind in source

“To confirm the impact of theranostic biomarkers on the response to everolimus, we compiled an independent cohort of 31 patients with DIPG with available sequencing data who were treated at Gustave Roussy with sirolimus or everolimus either before trial initiation or after randomization was stopped.”

ResultsFind in source

Sex is reported in Table 1 (balanced). Age is reported with median and ranges. Demographics include country of treatment. Health status is implied by inclusion criteria (Lansky score) but not explicitly detailed. Species/strain and housing are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for this human trial, including sex, age, and demographics, though health status is not explicitly detailed.

Evidence

“Male | 19 | 52.8 | 43 | 45.3 | 52 | 51.0 | 114 | 48.9”

Table 1Find in source

“Median age was 8.1 years (range, 1.8−30.3).”

ResultsFind in source

“France | 23 | 63.9 | 70 | 73.7 | 75 | 73.5 | 168 | 72.1”

Table 1Find in source

PASSReviewer 2· 90% conf

Patient demographics (age, sex) are reported; species/strain/housing are not applicable for a human trial.

Evidence

paraphrase[Table 1]

“Sex | Male | 19 | 52.8 | 43 | 45.3 | 52 | 51.0 | 114 | 48.9 | | Female | 17 | 47.2 | 52 | 54.7 | 50 | 49.0 | 119 | 51.1”

“Median | 9.5 | 7.8 | 8.1 | 8.1”

Table 1Find in source

The paper states that the trial was conducted in accordance with ethical principles but does not name the IRB/ethics committee that approved the study. Informed consent is implied by the mention of 'consented to biopsy' but not explicitly described. Regulatory compliance is mentioned (Declaration of Helsinki) but not detailed.

Sub-criteria

iacuc statementN/A

informed consentINADEQUATE

irb ethics statementINADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper mentions ethical conduct but does not name a specific ethics committee or provide an approval number, and informed consent is not explicitly described.

Evidence

“Patients with radiologically suspected DIPG first consented to biopsy.”

MethodsFind in source

absence[Full text]

No named ethics committee or approval number is provided.

“A radiotherapy-only control arm was deemed unethical; as parent associations considered the poor outcome with radiotherapy alone, they supported adjuvant treatment for all patients, consistent with registry data suggesting improved outcomes with any adjuvant therapy .”

Discussion ¶1Find in source

PASSReviewer 2· 90% conf

The trial is registered and reports ethics approval and informed consent; regulatory compliance is implied.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

“Patients with radiologically suspected DIPG first consented to biopsy.”

MethodsFind in source

absence[Whole paper]

No explicit ethics approval statement is found.

The three drugs (erlotinib, everolimus, dasatinib) are identified with doses and regimen. Statistical software (East, Cytel) is named. No antibodies, cell lines, or mycoplasma testing are applicable. Organisms are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drugs are identified with doses and regimens, and software tools are named, though some details like lot numbers are not provided.

Evidence

“Three drugs were compared: everolimus 5 mg m −2 per dose once daily, erlotinib 125 mg m −2 per dose once daily or dasatinib 85 mg m −2 per dose twice daily.”

MethodsFind in source

“East software; Cytel”

MethodsFind in source

“The authors declare that three drugs (everolimus, erlotinib and dasatinib) were supplied free of charge by the pharmaceutical companies (Novartis, F. Hoffman-La Roche and Bristol Myers Squibb, respectively).”

Competing interestsFind in source

PASSReviewer 2· 90% conf

The investigational drugs are identified with doses; software tools are named; no antibodies or cell lines are used.

Evidence

“Three drugs were compared: everolimus 5 mg m −2 per dose once daily, erlotinib 125 mg m −2 per dose once daily or dasatinib 85 mg m −2 per dose twice daily.”

MethodsFind in source

“East software; Cytel”

MethodsFind in source

The paper names tests (log-rank, Fisher's exact, chi-square, Wilcoxon) and reports HRs with 95% CIs. Exact p-values are given for many analyses. Assumptions are not explicitly verified but standard methods are used. Data presentation includes KM curves and forest plots. Mathematical plausibility is not applicable for large-N survival data.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals reported.

Evidence

“The hazard ratio (HR) stratified by PTEN status was HR (erlotinib/dasatinib) = 0.87 (95% CI: 0.52−1.46), P = 0.59.”

ResultsFind in source

“The HR stratified by EGFR status was HR (everolimus/dasatinib) = 0.89 (95% CI: 0.66−1.19), P = 0.42.”

ResultsFind in source

“East software; Cytel”

MethodsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and software is identified; exact p-values are often reported.

Evidence

paraphrase[Results, Survival analysis]

“The HR stratified by PTEN status was HR (erlotinib/dasatinib) = 0.87 (95% CI: 0.52−1.46), P = 0.59.”

“eye ( P < 0.0001), skin ( P = 0.004) and infectious ( P = 0.042) adverse events were more frequent with erlotinib”

ResultsFind in source

“median OS = 10.8 months (95% confidence interval (CI): 9.5−13.0)”

ResultsFind in source

Genomic data are deposited in EGA with an accession number. Clinical data are available upon reasonable request through a data transfer agreement, which is a legitimate managed-access route. Radiologic data are being uploaded to a repository. Code sharing is not mentioned, but no bespoke code is described.

Sub-criteria

code sharingNOT REPORTED

accession numbersADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is well described with a concrete access route for genomic data and a managed-access procedure for clinical data.

Evidence

“Genomic data are available through the European Genome-phenome Archive ( EGAS50000001164 (https://ega-archive.org/studies/EGAS50000001164) ).”

Data availabilityFind in source

“Clinical data (sex, age, OS and PFS) will be available upon reasonable request through the signature of a data transfer agreement because these data are sensitive and belong to the sponsor of the study.”

Data availabilityFind in source

absence[Full text]

Code sharing is not mentioned.

PASSReviewer 2· 90% conf

Data availability statement is concrete with a repository accession and managed access for clinical data; code is not applicable.

Evidence

“Genomic data are available through the European Genome-phenome Archive ( EGAS50000001164 (https://ega-archive.org/studies/EGAS50000001164) ).”

Data availabilityFind in source

The trial is registered (NCT02233049). Methods are detailed enough for replication. Limitations are discussed (e.g., lack of radiotherapy-only control, confounding by reirradiation). Conclusions are proportional to the evidence. Funding and COI are declared. A reporting guideline (CONSORT) is not explicitly mentioned, but the paper includes a CONSORT diagram.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, detailed methods, and discussion of limitations, though a reporting guideline is not explicitly referenced.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

Discussion ¶1Find in source

Competing interestsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, funding, and COI statements; limitations are discussed; conclusions are proportional.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

AcknowledgementsFind in source

Discussion ¶1Find in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 81 references by DOI: 79 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust overall, but readers should weigh the missing explicit ethics approval statement and the minor reporting gaps. An erratum or clarification adding the ethics committee name and approval number, and explicitly stating the open-label design, would strengthen the record.

1.
HIGHethics
Add the name of the ethics committee/IRB and the approval number to the Methods section.
The paper currently lacks an explicit ethics approval statement, which is a standard requirement for clinical trials.
2.
HIGHethics
Explicitly describe the informed consent process (written, oral, or waiver) in the Methods.
Informed consent is only implied by 'consented to biopsy' and should be clearly documented.
3.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or cover letter.
The paper includes a CONSORT diagram but does not explicitly reference the guideline, which is a common expectation.
4.
MEDIUMdata code
Provide a data availability statement for code, or state that no custom code was used.
Code sharing is not mentioned, and clarifying this would enhance reproducibility.
5.
MEDIUMreporting
Clarify the open-label design and rationale for lack of blinding in the Methods.
Blinding is not reported, and explicitly stating the open-label design would remove ambiguity.
6.
MEDIUMstatistics
Describe how outliers were handled in the statistical analysis, if applicable.
Outlier handling is not explicitly described, and adding this would improve methodological transparency.
7.
MEDIUMreporting
Include a statement on health status of participants beyond inclusion criteria, if available.
Health status is implied by inclusion criteria but not explicitly detailed.
8.
LOWcopyedit
Fix the typo 'identifiy' to 'identify' in the Introduction, paragraph 3.
Typographical errors should be corrected for professionalism.
9.
LOWcopyedit
Ensure consistent use of 'median OS' vs 'median overall survival' and consistent formatting of '95% CI' throughout the Results.
Inconsistent abbreviation usage can confuse readers.
10.
LOWcopyedit
Clarify whether patients with biomarker-negative tumors who received dasatinib without randomization were included in any analysis or safety population.
The current text is ambiguous about the inclusion of these patients.

Full text (105,889 chars · analyzed ~71%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.

Read full text (PMC)

DOI

10.1038/s41591-026-04354-1

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/fa641dcb-2c36-4303-bc65-4354347a1199" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/fa641dcb-2c36-4303-bc65-4354347a1199/badge" alt="Kaimen Rigor review — 3.5★ (Adequate), 0 critical, 2 high issues for “Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

faba59d259f111b807a2f665fd7a6d34af97ff722dff735cf20c5f38d98b76c7

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.5 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingEthical approvals partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Biggest issues

01Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary efficacy claim is that the trial was negative for OS, with no significant difference between treatment arms and historical control. However, the paper highlights a subgroup analysis showing that patients with PI3K/AKT/MTOR alterations treated with everolimus had a median OS of 14 months versus 9 months for dasatinib. This effect size is presented without an explicit anchor to a minimal clinically important difference or a clear biological meaningfulness threshold, and it is based on a post-hoc exploratory analysis.
“Patients harboring PIK3/AKT/MTOR pathway mutations, an mTOR activation gene expression signature or 1q gain derived greater benefit from everolimus than from dasatinib, with median OS of 14 months versus 9 months, respectively.”
Find in source
02Printed percentage does not match its own count
mediumArithmeticrecomputedFull detail
49% does not match the reported count 110/233
“110 of 233 patients (49%)”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

2 findings · worst medium

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks. 1 printed percentage that does not match its own count.

Overstated conclusions

2 findings · worst high

Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Ethics/consent reporting incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on DIPG biology, targeted therapies, and the rationale for biomarker-driven randomization.

Evidence

“In the past two decades, the reintroduction of stereotactic biopsies and increased autopsy studies – have helped identifiy actionable targets, such as PDGFRA – , EGFR , and mTOR .”

Introduction ¶1Find in source

Introduction ¶4Find in source

“The large cohort enabled exploration of disease heterogeneity within a single trial.”

Discussion ¶1Find in source

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior research on DIPG biology, targeted therapies, and the rationale for biomarker-driven randomization.

Evidence

“In the past two decades, the reintroduction of stereotactic biopsies and increased autopsy studies – have helped identifiy actionable targets, such as PDGFRA – , EGFR , and mTOR .”

Introduction ¶1Find in source

Introduction ¶4Find in source

paraphrase[Discussion, paragraph 1]

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsINADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The trial design is rigorous with clear randomization, pre-specified endpoints, and a power analysis, though blinding is not applicable in this open-label trial.

Evidence

paraphrase[Methods, Trial design and endpoints]

MethodsFind in source

PASSReviewer 2· 90% conf

The trial design is rigorous with clear randomization, power analysis, and inclusion criteria; blinding is not applicable for an open-label trial but is stated.

Evidence

paraphrase[Methods, Trial design and endpoints]

MethodsFind in source

ResultsFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Biological variables are well reported for this human trial, including sex, age, and demographics, though health status is not explicitly detailed.

Evidence

“Male | 19 | 52.8 | 43 | 45.3 | 52 | 51.0 | 114 | 48.9”

Table 1Find in source

“Median age was 8.1 years (range, 1.8−30.3).”

ResultsFind in source

“France | 23 | 63.9 | 70 | 73.7 | 75 | 73.5 | 168 | 72.1”

Table 1Find in source

PASSReviewer 2· 90% conf

Patient demographics (age, sex) are reported; species/strain/housing are not applicable for a human trial.

Evidence

paraphrase[Table 1]

“Sex | Male | 19 | 52.8 | 43 | 45.3 | 52 | 51.0 | 114 | 48.9 | | Female | 17 | 47.2 | 52 | 54.7 | 50 | 49.0 | 119 | 51.1”

“Median | 9.5 | 7.8 | 8.1 | 8.1”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentINADEQUATE

irb ethics statementINADEQUATE

regulatory complianceINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper mentions ethical conduct but does not name a specific ethics committee or provide an approval number, and informed consent is not explicitly described.

Evidence

“Patients with radiologically suspected DIPG first consented to biopsy.”

MethodsFind in source

absence[Full text]

No named ethics committee or approval number is provided.

Discussion ¶1Find in source

PASSReviewer 2· 90% conf

The trial is registered and reports ethics approval and informed consent; regulatory compliance is implied.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

“Patients with radiologically suspected DIPG first consented to biopsy.”

MethodsFind in source

absence[Whole paper]

No explicit ethics approval statement is found.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational drugs are identified with doses and regimens, and software tools are named, though some details like lot numbers are not provided.

Evidence

“Three drugs were compared: everolimus 5 mg m −2 per dose once daily, erlotinib 125 mg m −2 per dose once daily or dasatinib 85 mg m −2 per dose twice daily.”

MethodsFind in source

“East software; Cytel”

MethodsFind in source

Competing interestsFind in source

PASSReviewer 2· 90% conf

The investigational drugs are identified with doses; software tools are named; no antibodies or cell lines are used.

Evidence

“Three drugs were compared: everolimus 5 mg m −2 per dose once daily, erlotinib 125 mg m −2 per dose once daily or dasatinib 85 mg m −2 per dose twice daily.”

MethodsFind in source

“East software; Cytel”

MethodsFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedINADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Statistical methods are appropriate and well-described, with exact p-values and effect sizes with confidence intervals reported.

Evidence

“The hazard ratio (HR) stratified by PTEN status was HR (erlotinib/dasatinib) = 0.87 (95% CI: 0.52−1.46), P = 0.59.”

ResultsFind in source

“The HR stratified by EGFR status was HR (everolimus/dasatinib) = 0.89 (95% CI: 0.66−1.19), P = 0.42.”

ResultsFind in source

“East software; Cytel”

MethodsFind in source

PASSReviewer 2· 90% conf

Statistical tests are named, effect sizes with CIs are reported, and software is identified; exact p-values are often reported.

Evidence

paraphrase[Results, Survival analysis]

“The HR stratified by PTEN status was HR (erlotinib/dasatinib) = 0.87 (95% CI: 0.52−1.46), P = 0.59.”

“eye ( P < 0.0001), skin ( P = 0.004) and infectious ( P = 0.042) adverse events were more frequent with erlotinib”

ResultsFind in source

“median OS = 10.8 months (95% confidence interval (CI): 9.5−13.0)”

ResultsFind in source

Sub-criteria

code sharingNOT REPORTED

accession numbersADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is well described with a concrete access route for genomic data and a managed-access procedure for clinical data.

Evidence

“Genomic data are available through the European Genome-phenome Archive ( EGAS50000001164 (https://ega-archive.org/studies/EGAS50000001164) ).”

Data availabilityFind in source

absence[Full text]

Code sharing is not mentioned.

PASSReviewer 2· 90% conf

Data availability statement is concrete with a repository accession and managed access for clinical data; code is not applicable.

Evidence

“Genomic data are available through the European Genome-phenome Archive ( EGAS50000001164 (https://ega-archive.org/studies/EGAS50000001164) ).”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper is transparent with trial registration, detailed methods, and discussion of limitations, though a reporting guideline is not explicitly referenced.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

Discussion ¶1Find in source

Competing interestsFind in source

PASSReviewer 2· 90% conf

The paper is transparent with trial registration, funding, and COI statements; limitations are discussed; conclusions are proportional.

Evidence

“ClinicalTrials.gov: NCT02233049 (https://clinicaltrials.gov/study/NCT02233049) .”

AbstractFind in source

AcknowledgementsFind in source

Discussion ¶1Find in source

Registered (2 IDs: ClinicalTrials.gov, EudraCT). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 81 references by DOI: 79 verified — 2 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHethics
Add the name of the ethics committee/IRB and the approval number to the Methods section.
The paper currently lacks an explicit ethics approval statement, which is a standard requirement for clinical trials.
2.
HIGHethics
Explicitly describe the informed consent process (written, oral, or waiver) in the Methods.
Informed consent is only implied by 'consented to biopsy' and should be clearly documented.
3.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or cover letter.
The paper includes a CONSORT diagram but does not explicitly reference the guideline, which is a common expectation.
4.
MEDIUMdata code
Provide a data availability statement for code, or state that no custom code was used.
Code sharing is not mentioned, and clarifying this would enhance reproducibility.
5.
MEDIUMreporting
Clarify the open-label design and rationale for lack of blinding in the Methods.
Blinding is not reported, and explicitly stating the open-label design would remove ambiguity.
6.
MEDIUMstatistics
Describe how outliers were handled in the statistical analysis, if applicable.
Outlier handling is not explicitly described, and adding this would improve methodological transparency.
7.
MEDIUMreporting
Include a statement on health status of participants beyond inclusion criteria, if available.
Health status is implied by inclusion criteria but not explicitly detailed.
8.
LOWcopyedit
Fix the typo 'identifiy' to 'identify' in the Introduction, paragraph 3.
Typographical errors should be corrected for professionalism.
9.
LOWcopyedit
Ensure consistent use of 'median OS' vs 'median overall survival' and consistent formatting of '95% CI' throughout the Results.
Inconsistent abbreviation usage can confuse readers.
10.
LOWcopyedit
Clarify whether patients with biomarker-negative tumors who received dasatinib without randomization were included in any analysis or safety population.
The current text is ambiguous about the inclusion of these patients.

Full text (105,889 chars · analyzed ~71%, head + tail)Analyzed: Aug 15, 2026